Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARK trial of sulfadoxine-pyrimethamine in pregnancy to reduce small vulnerable newborns
ACTRN12626001191381Phase 3Not yet recruiting
- Sponsor
- Menzies School of Health Research
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Small for gestational age (SGA) and preterm birth comparing Sulfadoxine-pyrimethamine with Placebo (2 arms). Primary endpoint: Small vulnerable newborn. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
sulfadoxine + pyrimethamine
03
Conditions
Small for gestational age (SGA)preterm birth
Beyond the preview
Go deeper on ACTRN12626001191381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001191381.